{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:23:53Z","timestamp":1787239433919,"version":"build-2736575974"},"reference-count":94,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2025,6,3]]},"DOI":"10.1080\/17425255.2025.2499550","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:44:33Z","timestamp":1746193473000},"page":"649-663","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic considerations for gonadotropin-releasing hormone agonists and antagonists to treat endometriosis"],"prefix":"10.1080","volume":"21","author":[{"given":"Anna Maria","family":"Paoletti","sequence":"first","affiliation":[{"name":"University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Neri","sequence":"additional","affiliation":[{"name":"Agency of National Importance and High Specialization G. Brotzu","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Pilloni","sequence":"additional","affiliation":[{"name":"University-Hospital of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Marotto","sequence":"additional","affiliation":[{"name":"University-Hospital of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Giancane","sequence":"additional","affiliation":[{"name":"San Martino Hospital","place":["Oristano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7933-9757","authenticated-orcid":false,"given":"Valerio","family":"Vallerino","sequence":"additional","affiliation":[{"name":"San Michele Hospital","place":["Agency of National Importance and High Specialization G. Brotzu, Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Piras","sequence":"additional","affiliation":[{"name":"University-Hospital of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Melis","sequence":"additional","affiliation":[{"name":"University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Melis","sequence":"additional","affiliation":[{"name":"Degree Course in Medicine and Surgery, University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Danilo Maria","family":"Masciale","sequence":"additional","affiliation":[{"name":"Degree Course in Medicine and Surgery, University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Murgia","sequence":"additional","affiliation":[{"name":"University of Ferrara","place":["Ferrara, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Benedetto","family":"Melis","sequence":"additional","affiliation":[{"name":"University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00389-5"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2012.10.002"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1111445"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0426"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804690"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00242"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.13156"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.72707"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1121991"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)38580-6"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0399"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0b013e328348a3ce"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9803673"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101103240205"},{"key":"e_1_3_5_17_1","first-page":"802","volume-title":"Cancer medicine","author":"Schally AV","year":"2006","unstructured":"Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland J Frei E, editors. Cancer medicine. 7th ed. Hamilton: Decker; 2006. p. 802\u2013816.","edition":"7"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1520-6394(1998)7:4<171:aid-da5>3.0.co;2-d"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0b013e32833b35a7"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)58200-4"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0015-0282(98)00500-7"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(92)91706-g"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199039030-00007"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-68-6-1167"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xfre.2022.11.009"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199039040-00005"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039010-00003"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651020-00009"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.916279"},{"key":"e_1_3_5_30_1","unstructured":"Trelstar (triptorelin pamoate) Verity. Labeling-package insert. 2024. Available at Apr 12. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=022437"},{"key":"e_1_3_5_31_1","unstructured":"Lupron depot (leuprolide acetate). Abbvie endocrine inc. Labeling-package insert. 2020. Available at Mar 18. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020708"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241070-00003"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06797-6"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0015-0282(97)80071-4"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0015-0282(97)81407-0"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1310286"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a136219"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.5.1637"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00099a023"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/14.suppl_1.207"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-200109000-00024"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.15.2155"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.9.2392"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1472-6483(10)61590-8"},{"key":"e_1_3_5_45_1","unstructured":"News release from AEterna laboratories. 2004. Available from: http:\/\/www.prnewswire.co.uk\/cgi\/news\/release?id=123022"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043363983"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051085"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1695"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm8006454"},{"key":"e_1_3_5_50_1","unstructured":"AbbVie Inc. Prescribing information for OrilissaTM (elagolix) tablets for oral use. 2018 [cited 2018 Aug 15]. Available from: http:\/\/www.accessdata.fda.gov\/"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3845"},{"key":"e_1_3_5_52_1","volume-title":"United States package insert","author":"Orilissa\u2122(elagolix)","year":"2018","unstructured":"Orilissa\u2122(elagolix). United States package insert. North Chicago (IL): AbbVie Inc; 2018."},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0629-6"},{"key":"e_1_3_5_54_1","first-page":"S54","article-title":"Effects of the coadministration of single and multiple doses of rifampin on the pharmacokinetics and safety of elagolix in healthy premenopausal females","volume":"99","author":"Ng J","year":"2016","unstructured":"Ng J, Salem A, Carter D, et al. Effects of the coadministration of single and multiple doses of rifampin on the pharmacokinetics and safety of elagolix in healthy premenopausal females. Clin Pharmacol Ther. 2016;99:S54\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800223-0.00005-0"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13207"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00840-7"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.640"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1689"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/1933719114549848"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.5301\/je.5000157"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/1933719113497292"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.5301\/je.5000211"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1700089"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002675"},{"key":"e_1_3_5_67_1","unstructured":"Elagolix multidiscipline review US FDA center for drug evaluation and research. 2018 [cited 2018 Jul]. Available from: https:\/\/www.accessdata.fda.gov\/drugs.atfda_docs\/nda\/2018\/210450Orig1s000MultiD.pdf"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0977-4"},{"key":"e_1_3_5_69_1","unstructured":"Takeda Roivant Sciences. Roivant sciences and Takeda launch myovant sciences to develop innovative therapeutics for women\u2019s health and prostate cancer. Media release. 2016 Jun 6. Available from: https:\/\/www.takeda.com"},{"key":"e_1_3_5_70_1","unstructured":"Takeda Aska Pharmaceutical. ASKA and Takeda enter into licensing agreement for relugolix in women\u2019s health indications. Media release. 2018 May 31. Available from: http:\/\/www.takeda.com"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.12.001"},{"key":"e_1_3_5_72_1","unstructured":"Myovant Sciences. Relugolix Japanese prescribing information. 2019 [cited 2019 Mar 7]. Available from: http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_2499013F1027_1_02"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342010-00003"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xfre.2022.11.010"},{"issue":"1","key":"e_1_3_5_75_1","first-page":"i267","article-title":"Pharmacokinetics, pharmacodynamics, and safety of relugolix, a potent oral once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist, as monotherapy and in combination with estradiol\/norethindrone acetate add-back therapy [abstract no. P-287]","volume":"32","author":"Lukes A","year":"2017","unstructured":"Lukes A, Johnson B, Jones L, et al. Pharmacokinetics, pharmacodynamics, and safety of relugolix, a potent oral once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist, as monotherapy and in combination with estradiol\/norethindrone acetate add-back therapy [abstract no. P-287]. Hum Reprod. 2017;32(Suppl 1):i267\u20138.","journal-title":"Hum Reprod"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.07.055"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-021-01393-3"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2021.11.013"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2006.160"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0029-7844(99)00358-0"},{"key":"e_1_3_5_81_1","first-page":"i267","article-title":"Pharmacokinetics, pharmacodynamics, and safety of relugolix, a potent oral once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist as monotherapy and in combination with estradiol\/norethisterone acetate add-back therapy","volume":"32","author":"Lukes A","year":"2017","unstructured":"Lukes A, Johnson B, Jones L, et al. Pharmacokinetics, pharmacodynamics, and safety of relugolix, a potent oral once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist as monotherapy and in combination with estradiol\/norethisterone acetate add-back therapy. Hum Reprod. 2017;32:i267\u2013268(abstr).","journal-title":"Hum Reprod"},{"key":"e_1_3_5_82_1","unstructured":"Ryeqo (relugolix 40 mg estradiol 1\u00b70 mg and norethisterone acetate 0\u00b75 mg) \u2013 summary of products characteristics. 2021 Jul 20 [cited 2021 Aug 22]. Available from: https:\/\/ec.europa.eu\/health\/documents\/communityregister\/2021\/20210716152087\/anx_152087_en.pdf"},{"key":"e_1_3_5_83_1","unstructured":"Myovant Sciences. Myfembree (relugolix estradiol and norethindrone acetate) tablets prescribing information. 2021 [cited 2021 Aug 22]. Available from: https:\/\/www.myovant.com\/wpcontent\/uploads\/2021\/05\/ApprovedMYFEMBREEPIandPPI_26May2021.pdf"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00622-5"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dead263"},{"key":"e_1_3_5_86_1","unstructured":"Myovant Sciences Inc. MYFEMBREE\u00ae (relugolix estradiol and norethindrone acetate) tablets for oral use: US prescribing information. 2023 [cited 2024 Feb 28]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=fc3feb73-cc84-43a8-aa32-b262460495e8"},{"key":"e_1_3_5_87_1","unstructured":"Gedeon Richter Plc. Ryeqo (relugolix\/estradiol\/norethisterone acetate) 40 mg\/1 mg\/0.5 mg film-coated tablets: EU summary of product characteristics. 2021 [cited 2024 Feb 28]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ryeqo-epar-product-information_en.pdf"},{"key":"e_1_3_5_88_1","unstructured":"ObsEva. ObsEva provides update on Yselty\u00ae (linzagolix) clinical development program. Media release. 2021 Jan 11. Available from: http:\/\/www.obseva.com"},{"key":"e_1_3_5_89_1","unstructured":"Theramex. Theramex announces European Commission marketing authorization for Yselty\u00ae (linzagolix) an oral GnRH antagonist for the treatment of symptoms of uterine fibroids. Media release. 2022 Jun 11. Available from: https:\/\/www.theramex.com\/"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13688"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15171"},{"key":"e_1_3_5_92_1","unstructured":"European Medicines Agency. Linzagolix: EU summary of product characteristics. 2022 [cited 2022 Jun 21]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1606.htm"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01875"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.02.114"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deae076"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2025.2499550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T09:57:38Z","timestamp":1747994258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2025.2499550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["10.1080\/17425255.2025.2499550"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2025.2499550","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}